Two Techniques of Temporal Migraine Surgery Are 'Equally Effective'

Article ID: 636310

Released: 29-Jun-2015 10:35 AM EDT

Source Newsroom: Wolters Kluwer Health: Lippincott Williams and Wilkins

Newswise — June 29, 2015 – Two migraine surgery techniques targeting a specific "trigger site" are both highly effective in reducing the frequency and severity of migraine headaches, according to a randomized trial in the July issue of Plastic and Reconstructive Surgery®, the official medical journal of the American Society of Plastic Surgeons (ASPS).

Patients with temporal-type migraine derive similar and significant improvement from techniques that relieve pressure on (decompression) or remove a portion of (neurectomy) the nerve responsible for triggering their headaches, reports the study by ASPS Member Surgeon Bahman Guyuron, MD, Emeritus professor of plastic surgery at Case School of Medicine, Cleveland, and colleagues.

Both Approaches Effective for Temporal Migraine SurgeryDr. Guyuron developed the migraine surgery techniques after noticing that some migraine patients had reduced headache activity after undergoing cosmetic forehead lift procedures. The surgery targets trigger sites in the nerve branches that produce headaches, identified by preoperative evaluation. Trigger sites are detected using a constellation of symptoms, nerve blocks, ultrasound Doppler and CT scans.

The study included 20 patients with the temporal type of migraine headaches—one of the two most common trigger sites. All had severe and frequent migraine attacks despite standard medications. The patients underwent surgery on both sides of the head, targeting the nerve implicated in temporal migraine headaches: the zygomaticotemporal branch of the trigeminal nerve (ZTBTN).

On one side, a decompression procedure was performed to relieve pressure placed on the nerve by surrounding tissues. On the other side, a neurectomy procedure was performed, in which a small piece of the nerve was removed. Neurectomy of the ZTBTN has long been performed as part of several plastic and neurosurgery procedures for decades, with no apparent complications.

To assess the relative effectiveness of the two techniques, outcomes were compared between sides one year after surgery. In nearly 90 percent of operated sites, surgery produced at least a one-half reduction in migraine frequency, days with migraine, and headache severity and duration.

The results were almost identical between sides. Migraine frequency decreased from 14.6 to 2.2 per month with nerve decompression and from 14.2 to 1.9 per month with neurectomy. Migraine severity (on a ten-point scale) decreased from 7.0 to 2.9 with decompression and from 6.8 to 2.6 with neurectomy.

Both techniques also reduced migraine-related disability. There were no complications of either procedure.

Migraine surgery has emerged as an effective option for patients who don't respond to the limited medication options for treating migraine headaches. Since 2000, Dr. Guyuron and his team have published 24 articles in peer-reviewed journals on migraine surgery and its efficacy, with another 12 research projects in process. Five independent centers have confirmed Dr. Guyuron's findings.

The new trial adds to the evidence by showing that decompression and neurectomy are "equally effective" techniques for treatment of appropriate patients with temporal migraine headaches. Dr. Guyuron and colleagues conclude, "Both procedures can be performed safely with significant improvement in symptom burden, without concern for great morbidity [complications]." They add that patients who don't get adequate relief from initial decompression surgery might still benefit from neurectomy as a second option.

Click here to read "A Prospective Randomized Outcomes Comparison of Two Temple Migraine Trigger Site Deactivation Techniques."

Article: "A Prospective Randomized Outcomes Comparison of Two Temple Migraine Trigger Site Deactivation Techniques" (doi: 10.1097/PRS.0000000000001322)

Plastic and Reconstructive Surgery® is published by Wolters Kluwer.

###

About Plastic and Reconstructive SurgeryFor more than 60 years, Plastic and Reconstructive Surgery® (http://journals.lww.com/plasreconsurg/) has been the one consistently excellent reference for every specialist who uses plastic surgery techniques or works in conjunction with a plastic surgeon. The official journal of the American Society of Plastic Surgeons, Plastic and Reconstructive Surgery® brings subscribers up-to-the-minute reports on the latest techniques and follow-up for all areas of plastic and reconstructive surgery, including breast reconstruction, experimental studies, maxillofacial reconstruction, hand and microsurgery, burn repair, and cosmetic surgery, as well as news on medico-legal issues.

About ASPSThe American Society of Plastic Surgeons (ASPS) is the world's largest organization of board-certified plastic surgeons. Representing more than 7,000 Member Surgeons, the Society is recognized as a leading authority and information source on aesthetic and reconstructive plastic surgery. ASPS comprises more than 94 percent of all board-certified plastic surgeons in the United States. Founded in 1931, the Society represents physicians certified by The American Board of Plastic Surgery or The Royal College of Physicians and Surgeons of Canada. ASPS advances quality care to plastic surgery patients by encouraging high standards of training, ethics, physician practice and research in plastic surgery. You can learn more and visit the American Society of Plastic Surgeons at www.plasticsurgery.org or www.facebook.com/PlasticSurgeryASPS and www.twitter.com/ASPS_news.

About Wolters KluwerWolters Kluwer is a global leader in professional information services. Professionals in the areas of legal, business, tax, accounting, finance, audit, risk, compliance and healthcare rely on Wolters Kluwer’s market leading information-enabled tools and software solutions to manage their business efficiently, deliver results to their clients, and succeed in an ever more dynamic world.

Wolters Kluwer reported 2014 annual revenues of €3.7 billion. The group serves customers in over 170 countries, and employs over 19,000 people worldwide. The company is headquartered in Alphen aan den Rijn, the Netherlands. Wolters Kluwer shares are listed on NYSE Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Wolters Kluwer has a sponsored Level 1 American Depositary Receipt program. The ADRs are traded on the over-the-counter market in the U.S. (WTKWY).

For more information about our products and organization, visit www.wolterskluwer.com, follow @WKHealth or @Wolters_Kluwer on Twitter, like us on Facebook, follow us on LinkedIn, or follow WoltersKluwerComms on YouTube.


Comment/Share





Chat now!